REPORT ON THE EARLY EFFICACY AND SAFETY OF MESENCHYMAL STROMAL CELLS (MSCS–OBNITIX (SIE 2026) - Oct 6, 2026 - Abstract #C091; Pres time: Sep 23, 2026; 02:15 PM - 03:45 PM; Location: HALL 3; "Graft versus host disease (GvHD) remains a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and patients with steroid- and ruxolitinib-refractory (SRR-GVHD) GvHD have limited treat- ment options...Our data show that MSCs cell therapy pro- vides an improvement in heavily pretreated GvHD, including both gastrointestinal and cutaneous manifestations, allowing discontinuation or reduction of immunosuppressive therapy in about 6/14 (43%)% of cases, and without adverse events. These results encourage further and earlier exploration of MSCs either alone or in combination for GvHD prophylaxis and treatment."
Clinical • Stroma • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia
|
|
G. Magliano1; D. Avenoso1; F. Saraceni2; Am. Raiola3; L. Castagna4; N. Polverelli5; P. Chiusolo6; S. Sica6; F. Patriarca7; C. Skert8; V. Radici1; M. Farina1; E. Morello1; F. Bonati1; P. Clementi1; M. Malagola1; D. Russo1
|